Evidence map›Paper›PMID 29504053›Full record

ArticleObesity surgery2018

Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).

Nina Riedel, Katharina Laubner, Anne Lautenbach, Gerhard Schön, Matthias Schlensak, Rainer Stengel, Thomas Eberl, Frank Dederichs, Jens Aberle, Jochen Seufert

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02731859 (EndoBarrier Register Deutschland), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02731859 unknown statusnot on this map

EndoBarrier Register Deutschland

Typeobservational_patient_registrySponsorUniversitätsklinikum Hamburg-EppendorfRan2014 to 2019Enrolled1,000ConditionsObesity, Diabetes MellitusArmsInsertion of EndoBarrier for approximately one year
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Nina RiedelDepartment for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. ni.sauer@uke.de.ORCID 0000-0002-8339-461X
Katharina LaubnerDivision of Endocrinology and Diabetology, Department of Medicine II, University Hospital of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany.
Anne LautenbachDepartment for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Gerhard SchönInstitute of Medical Biometry and Epidemiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Matthias SchlensakDepartment of Surgery, Schön Klinik Düsseldorf SE & Co. KG, Düsseldorf, Germany.
Rainer StengelDiakonissenanstalt Emmaus, Niesky, Germany.
Thomas EberlDonau-Ries-Klinik, Donauwörth, Germany.
Frank DederichsDepartment of Internal Medicine/Gastroenterology, Marienhospital Gelsenkirchen, Gelsenkirchen, Germany.
Jens AberleDepartment for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Jochen SeufertDivision of Endocrinology and Diabetology, Department of Medicine II, University Hospital of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany.
Universität Hamburg · DEUniversity of Freiburg · DEFernUniversität in Hagen · DEKlinik Donaustauf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA novel-approach for treatment of obesity and diabetes mellitus type 2 (T2DM) is represented by the endoscopic duodenal-jejunal bypass liner (DJBL). Recent data from the German DJBL registry provide evidence for substantial efficacy of the DJBL during the implantation period in obese patients with T2DM. However, little is known about the trends of glycemic control, BMI, and comorbidities after explantation of the DJBL, which have been investigated in the registry in this report.

methodsPatients were selected from the registry if they had a dataset at implantation, explantation, and at least one time point after explantation of the DJBL (n = 77). We also investigated a subgroup of patients with available data at least 1 year (-2 weeks) after explantation of the DJBL (n = 32).

resultsFor a mean BMI at implantation and a mean follow-up period, an increase of BMI of 2.1 kg/m

conclusionWith this data, we show that improvement of HbA1c and BMI can be partly maintained over a time of nearly 1-year postexplantation of the DJBL. However, for HbA1c, this may be biased by intensified medical treatment and effects deteriorated with time after explantation. These results suggest that implantation of the DJBL needs to be integrated in a long-term weight management program as most of other interventions in obese patients with T2DM.

trial registrationClinicalTrials.gov Identifier: NCT02731859.

Indexed as

Body Mass IndexBody-Weight TrajectoryDevice RemovalObesity, MorbidAdultBariatric SurgeryBlood GlucoseComorbidityDiabetes Mellitus, Type 2DuodenumFemaleFollow-Up StudiesGermanyGlycated HemoglobinHumansJejunumBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanDiabetes mellitus type 2DJBLFollow-upPostexplantation

Identifiers

PMID29504053
OpenAlexW2792242481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.